Sanguine Biosciences Partners with BroadOak
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine and cell & gene therapy R&D. Our investment will help Sanguine expand laboratory operations, leukapheresis offerings, and their patient donor network. The full press release is below. WALTHAM, Mass., Jan. 9, 2023 /PRNewswire/ — Sanguine Biosciences (“Sanguine”), a leader […]
BroadOak Invests in CDI Laboratories
BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below. BALTIMORE, Jan. 9, 2023 /PRNewswire/ — CDI Laboratories, Inc (“CDI Labs”) announced today that it has received a significant investment from BroadOak Capital Partners (“BroadOak”) […]
PBS Biotech Raises $22M
BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million financing that will be used to improve the company’s products portfolio, expand its process development services capability, and increase customer support for global cell therapy clients. The full press release is below. CAMARILLO, Calif., Jan. 9, 2023 /PRNewswire/ — PBS Biotech […]